Allergan aesthetics chief David Moatazedi becomes CEO of Evolus; CARB-X invests $6.2M into Melinta's next-gen antibiotics
→ Allergan aesthetics chief David Moatazedi is leaving to take the helm of Evolus, a much smaller biotech developing a rival to Botox. Evolus’ new drug DWP-450 (PrabotulinumtoxinA) is under review. Moatazedi noted: “The team at Evolus has done a fantastic job in bringing forward what I believe will be the most exciting new product in aesthetics. I look forward to working with this talented group of professionals and completing the build out of a best in class leadership team.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.